Celldex Therapeutics (CLDX) Income from Continuing Operations (2016 - 2025)
Historic Income from Continuing Operations for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$67.0 million.
- Celldex Therapeutics' Income from Continuing Operations fell 5917.0% to -$67.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.5 million, marking a year-over-year decrease of 4572.71%. This contributed to the annual value of -$157.9 million for FY2024, which is 1162.0% down from last year.
- Celldex Therapeutics' Income from Continuing Operations amounted to -$67.0 million in Q3 2025, which was down 5917.0% from -$56.6 million recorded in Q2 2025.
- Over the past 5 years, Celldex Therapeutics' Income from Continuing Operations peaked at -$13.4 million during Q2 2021, and registered a low of -$67.0 million during Q3 2025.
- In the last 5 years, Celldex Therapeutics' Income from Continuing Operations had a median value of -$32.8 million in 2024 and averaged -$34.7 million.
- In the last 5 years, Celldex Therapeutics' Income from Continuing Operations crashed by 16922.9% in 2022 and then skyrocketed by 1528.16% in 2023.
- Celldex Therapeutics' Income from Continuing Operations (Quarter) stood at -$20.1 million in 2021, then plummeted by 31.46% to -$26.5 million in 2022, then crashed by 63.5% to -$43.3 million in 2023, then dropped by 8.74% to -$47.1 million in 2024, then plummeted by 42.37% to -$67.0 million in 2025.
- Its Income from Continuing Operations was -$67.0 million in Q3 2025, compared to -$56.6 million in Q2 2025 and -$53.8 million in Q1 2025.